Intravitreal Bevacizumab for Diabetic Macular Edema
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have
demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of
edema.
This study designed to evaluate the effect of Intravitreal injection of a recombinant
monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.